Combined company expected to advance differentiated oral obesity franchise led by CX11, a clinical-stage, once-daily oral small-molecule GLP-1 receptor agonist ("RA"), and CX12, a preclinical oral small-molecule
WESTFIELD, N.J., May 19, 2026 (GLOBE NEWSWIRE) -- Amanat Acquisition Corp (the "Company"), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company, today announced the pricing